Prognostic value of systemic inflammation response index in patients with glioma: a meta-analysis
- PMID: 40486512
- PMCID: PMC12141222
- DOI: 10.3389/fimmu.2025.1576845
Prognostic value of systemic inflammation response index in patients with glioma: a meta-analysis
Abstract
Background: The systemic inflammation response index (SIRI) has been investigated for its prognostic relevance in patients with glioma; however, findings remain inconsistent. Therefore, this meta-analysis aimed to clarify the prognostic value of SIRI in glioma.
Methods: PubMed, Web of Science, Embase, Cochrane Library, and CNKI were systematically searched through December 28, 2024. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to assess the association between SIRI and glioma prognosis.
Results: A total of 10 studies including 1,942 participants were analyzed. Elevated SIRI was significantly associated with poorer overall survival (OS) (HR=1.67, 95% CI=1.46-1.91, p<0.001) and shorter progression-free survival (PFS) (HR=1.80, 95% CI=1.29-2.52, p=0.001). Subgroup analyses indicated that the prognostic value of SIRI for OS and PFS was consistent regardless of sample size, pathological subtype, cutoff value, or type of survival analysis (p<0.05). Sensitivity and publication bias analyses confirmed the robustness of the results.
Conclusion: This meta-analysis demonstrates that high SIRI is a significant predictor of OS and PFS in patients with glioma. SIRI may serve as a promising prognostic biomarker in glioma-related clinical practice.
Keywords: biomarker; glioma; meta-analysis; prognosis; systemic inflammation response index.
Copyright © 2025 Jiang and Zhou.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




